Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HUCMSC-derived Secretome in Liver Cirrhosis
NCT06629909Phase 1Not yet recruiting
- Sponsor
- Baermed
- Start
- Dec 2024
- Primary completion
- Oct 2025
- Modality
- Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label trial of human umbilical cord mesenchymal stem cell secretome in Liver cirrhosis (LC) (2 arms), sponsored by Baermed. Primary endpoints: Liver Stiffness Measurement via Fibroscan at 10 months, Mac-2 Binding Protein Glycosylation Isomer at 10 months and 5 more. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
human umbilical cord mesenchymal stem cell secretome
03
Conditions
Liver cirrhosis (LC)
Beyond the preview
Go deeper on NCT06629909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06629909.